← Back to Clinical Trials
Recruiting NCT03375619

NCT03375619 Long-term Follow-up Study of Patients Receiving CAR-T Cells

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03375619
Status Recruiting
Phase
Sponsor Medical College of Wisconsin
Condition Chronic Lymphocytic Leukemia
Study Type OBSERVATIONAL
Enrollment 500 participants
Start Date 2017-12-01
Primary Completion 2035-01-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type OBSERVATIONAL
Interventions
Long-Term Follow-Up of Participants who Received CAR-T cells

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 500 participants in total. It began in 2017-12-01 with a primary completion date of 2035-01-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This protocol is designed as a long-term follow-up study of participants who will receive CAR-T cells as part of a clinical trial at the Medical College of Wisconsin/ Froedtert Hospital. The clinical trials include the following: Phase 1 Study of CAR-20/19-T Cells in Patients with Relapsed Refractory B Cell Malignancies (NCT03019055); Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma (NCT05976555); CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies (NCT05094206); LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies (NCT05990465); CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies (NCT04186520)

Eligibility Criteria

Inclusion Criteria: * All participants who enrolled in a CAR-T study at Froedtert Hospital \& the Medical College of Wisconsin. Exclusion Criteria: * There are no exclusion criteria for this study.

Contact & Investigator

Central Contact

Medical College of Wisconsin Clinical Cancer Center

✉ cccto@mcw.edu

📞 414-805-8900

Principal Investigator

Nirav Shah

PRINCIPAL INVESTIGATOR

Medical College of Wisconsin

Frequently Asked Questions

Who can join the NCT03375619 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Chronic Lymphocytic Leukemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03375619 currently recruiting?

Yes, NCT03375619 is actively recruiting participants. Contact the research team at cccto@mcw.edu for enrollment information.

Where is the NCT03375619 trial being conducted?

This trial is being conducted at Milwaukee, United States.

Who is sponsoring the NCT03375619 clinical trial?

NCT03375619 is sponsored by Medical College of Wisconsin. The principal investigator is Nirav Shah at Medical College of Wisconsin. The trial plans to enroll 500 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology